key: cord-0963236-75wzvhgu
authors: Sato, Itaru
title: Lip Ulcer Induced by Nivolumab: A Case Report
date: 2021-06-19
journal: Intern Med
DOI: 10.2169/internalmedicine.7151-21
sha: 37042be3ee6cf10f0a44c5b723b8468b505b2e94
doc_id: 963236
cord_uid: 75wzvhgu

nan

An 84-year-old man received nivolumab for the treatment of pleural mesothelioma and thereafter showed a partial response. After 6 cycles of treatment, the appearance of a lip ulcer was noticed. During the Coronavirus Disease 2019 pandemic, the patient used masks regularly and, consequently, his mouth was hidden and he thus had not noticed the lip ulcer.

After 11 cycles of the treatment, the patient consulted his physician about the lip ulcer (Picture a). He had no history of smoking and had never had ulcers before. Actinic keratosis and contact dermatitis were considered in the differential diagnoses, but the probability was considered to be low because of the short time to the onset, the presence of a localized ulcer in the lip and the absence of any possible allergens. Herpes Simplex was suspected; however, the use of vidarabine did not improve the ulcer. The nivolumab treatment was continued, but a decrease in the quality of life was noticed due to the pain caused by the lip ulcer. Based on a diagnosis of grade 2 immune-related adverse events (irAEs), prednisolone at 10 mg/day was orally administered for 2 weeks and the lip ulcer thereafter rapidly improved (Picture b). irAEs are a wide variety of side effects that can appear throughout the entire body, with variable time and site of onset (1). More than one-third of patients experience cutaneous AEs, usually in the form of a maculopapular rash, pruritus or vitiligo (2) . Although the occurrence mechanism of irAEs is not fully clear yet, effector T cells are considered to injure the tissue by blocking the control by regulatory T cells. As the lip is formed from the skin and mucosa, the effector T cells might have damaged the keratinocytes of the lip, thus resulting in lip ulceration. Several cases of nivolumab-associated lichenoid planus drug eruption have been reported, and the underlying mechanism seems to be related with the T-cell-mediated attack on keratinocytes. Unfortunately, this clinical case could not be confirmed because a biopsy was not performed, but a similar phenomenon might have occurred on this patient's lip. However, to the best of our knowledge there have so far been no reports on irAEs involving the lips, including lip ulcers. As a result, this makes our case a rare one.

Department of Medical Oncology, Ageo Central General Hospital, Japan Received: January 26, 2021; Accepted: May 5, 2021; Advance Publication by J-STAGE: June 19, 2021 Correspondence to Dr. Itaru Sato, sato.i@ach.or.jp

Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline

Dermatologic toxicities of immune checkpoint inhibitors

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license